241 Users Online
Bispecific Antibodies Market Segmented By Blinatumab, Catumaxomab and Duligotumab drug type used in Cancer, Infectious Disease, Inflammatory and Autoimmune Disorders, CNS Disorders
Bispecific antibodies contain two different antigen-binding sites in one molecule. Bispecific antibodies come in numerous formats, extending from moderately small proteins, merely comprising of two linked antigen-binding fragments, to large immunoglobulin G (IgG)-like molecules with added domains attached.
The clinical success of the currently marketed bispecific antibodies available in the bispecific antibodies market has amplified the intensive pace of development for bispecific antibodies in oncology. There are 106 bispecific antibody molecules currently in the pipeline, according to Globaldata’s database. Moreover, there are 263 ongoing to enroll clinical trials involving a bispecific antibody.
Of the 106 bispecific antibody agents that are currently in clinical development, 45 are purposed predominantly for blood cancers and the rest for solid tumours – mainly lung cancers and gastrointestinal.
Thus, the increasing research & development activities and the rising demand for bispecific antibodies to treat different types of cancer is expected to boost the demand for the global bispecific antibodies market.
Additionally, the manufacturers in the market are collaborating with regional biotech companies for the development of bispecific antibodies. These efforts by the manufacturers will also help the global bispecific antibodies market to grow at an unprecedented rate.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The key players in the global bispecific antibodies market are focusing on developing and introducing new products in the market. These drugs are still under pipeline and currently predict bright outcome in the future.
The manufacturers are constantly working on developing these products as the rising prevalence of cancer demands for better therapeutic treatment. The successful clinical trial outcomes projects optimistic future for the global bispecific antibodies market as well as the manufacturers.
For instance, In December 2020, Pfizer reported positive clinical data for BCMA-CD3 bispecific antibody in multiple myeloma.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionDespite numerous action and prevention plans by various organizations, the rate at which cancer prevalence is on a continuous rise. Although the prevalence of the disease is higher in developed countries, developing countries like India and China have also observed significant rise in prevalence rate over the course of time.
According to Globocan’s 2018 estimates, about 4,285,033 new cancer cases were diagnosed in China in 2018. Thus, the rising prevalence of cancer across the globe calls for more treatment options leading to rise in demand for bispecific antibodies.
According to WHO, cancer is the world’s second leading killer after cardiovascular diseases. However, it is also one of the most avoidable non-communicable chronic disease. Approximately, around 40% of all cancer deaths can be prevented through reduced use of tobacco, improved diets and physical activity, lowering alcohol consumption, etc.
There is a notable rise in adoption of sedentary lifestyle which indicates a large number of people are in active putting them at a higher risk of developing cancer. In addition, the consumption of fast-food and packaged material which is a part of sedentary lifestyle also projects higher risk of developing cancer. Thus, an upsurge in adoption of sedentary lifestyle reflects more number of cancer cases that will demand for better cancer therapeutics.
Sales Team
Client Partner
Like any other cancer therapeutics, bispecific antibodies also have major side effects which is the prime factor restraining the growth of the bispecific antibodies market. Additionally, the high cost of the drugs may also hamper the growth of the global bispecific antibodies market. Moreover, the rejection of the products that are currently under clinical trials may also restrict the growth of the bispecific antibodies market.
Based on drug type, the bispecific antibodies market has been segmented as
Based on indication, the bispecific antibodies market has been segmented as
Based on distribution channel, the bispecific antibodies market has been segmented as
Based on the region, the bispecific antibodies market has been segmented as
Key players operating in the global bispecific antibodies market include
Key players in the global bispecific antibodies market are focusing on carrying out partnerships to deliver exciting portfolio of new and established biologics medicine to patients with quality. Moreover, key players in the bispecific antibodies market are aiming to expand its presence in the Asia pacific region through partnerships.
Key manufacturers in the global bispecific antibodies market are also aiming to carry out acquisitions of the companies that offer specialized products and projects potential to generate substantial revenue. By acquiring these companies, manufacturers in the market aim to have a stronger product portfolio as compared to its competitors.
Thus, the increasing strategic development activities carried out by the manufacturers in the global bispecific antibodies market will have a positive impact leading to a significant growth in the market during the forecast period.
High prevalence of cancer coupled with high rate of acceptance of bispecific antibodies among clinicians and patients due to target specific treatment represents lucrative growth opportunities. A large number of products are under clinical trials that project positive outcomes in future. Thus, the strong product pipeline in the global bispecific antibodies market also predicts considerable growth opportunities in the market.
Moreover, the potential that bispecific antibodies represent as novel approach for immunotherapies to treat cancer is also driving the market growth which represents great opportunity for the manufacturers operating in the market.
Manufacturers in the market can focus on developing countries that represent lucrative growth opportunities due to rising disposable income and adoption of western lifestyle which is leading to a rise in prevalence of cancer. This will help the manufacturers to generate higher revenue during the forecast period.
It is quite evident that the prevalence of cancer is highest among the developed countries, U.S. being as the most developed amongst all represent high prevalence of cancer. The rising unhealthy lifestyle habits could be the major reason for the growing prevalence of cancer in the country. The high prevalence of cancer demand for higher adoption of cancer treatment, leading to a rise in demand for bispecific antibodies.
Moreover, the presence of major key players in the market and increasing R&D activities for the bispecific antibody in the country is another factor that makes U.S. a dominant player in the global bispecific antibody.
Germany dominates the global bispecific antibodies market and will continue to do so during the forecast period as well. The availability of a good healthcare infrastructure and facilities is the major factor that is contributing to Germany’s overall growth in the global bispecific antibodies market.
Moreover, the presence of well-trained medical professionals in the country along with the availability of medical procedures for the treatment of cancer represent considerable growth in the global bispecific antibodies market.
The pandemic has a rather mixed impact on the global bispecific antibodies market. The lockdown in the first half of 2020 led to severe disruption in the supply chain. Moreover, the shutting down of all the industries during due to the pandemic may have also disrupted the research activities that were being carried out for the drugs in pipeline.
This may have resulted in delayed development process. However, as these drugs are used for the treatment of cancer which is chronic in nature, the treatment adoption may have not been negatively affected by the pandemic. Therefore, the fall in sales is not quite big enough to affect the market negatively at a high rate.
Additionally, with the economies opening up and the introduction of vaccines, the manufacturers have commenced with the research & development activities at full pace and are focusing on launching the products as soon as possible in the market. This is expected to yield in substantial revenue in the bispecific antibodies market during the forecast period.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
